Keywords: good, efficacy, early, data, mva-bn-her2, kvistgard, denmark-based
Good efficacy in early data on MVA-BN-HER2
Article | 06 November 2006
Kvistgard, Denmark-based Bavarian Nordic says that novel preclinical study data show that its MVA-BN-HER2 vaccine has "exceptional and significant efficacy," ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
